Indaptus Therapeutics CSO to speak on webinar about cancer immunotherapy

Indaptus Therapeutics announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will participate as a panelist in an upcoming webinar hosted by Lumanity. The webinar, titled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as a ‘Next Big Thing’ in Cancer Immunotherapy,” will be held on October 23, 2024. The webinar will explore the next frontier in cancer immunotherapy: harnessing the power of innate immunity. A distinguished panel of biotech leaders will explore strategies for modulating innate immune pathways, either independently or in combination with checkpoint inhibitors, to help patients’ immune systems better control cancer. Dr. Newman will share insights from Indaptus’ pioneering work with its Decoy20 platform, which leverages killed, non-pathogenic Gram-negative bacteria to stimulate both innate and adaptive immune responses. Indaptus’ unique “pulse-prime” approach could offer a new path forward in immunotherapy, targeting hard-to-treat cancers that have not responded to other therapies.